

Centre hospitalier universitaire vaudois

Optimization of the biodistribution of 1C1m-Fc, an anti TEM-1 fusion protein antibody, un soft tissue sarcoma model in mice



UNIL | Université de Lausanne

R-OHP-18

Delage Judith¹; Fierle Julie²; Faivre-Chauvet Alain³; Schaefer Niklaus⁴; Coukos George⁵; Dunn Steven²; Viertl David⁴; Prior John⁴

- 1: Radiopharmacy unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 2: L-AbCore, Ludwig Center for Cancer, Research, Lausanne, Switzerland
- 3: Radiopharmacy unit, Nantes University Hospital and University of Nantes, Nantes, France
- 4: Service of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

5: Service of oncology. Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Introduction

1C1m-Fc is an anti TEM-1 scFv-Fc fusion antibody developed in Lausanne. Our previous study showed the interest of this new compound radiolabeled with ¹⁷⁷Lu for molecular imaging in soft tissue sarcoma.

Conclusion :

The number of DOTA molecules attached per antibody moiety plays a significant role in determining successful tumor targeting with radiolabeled antibodies. 1 DOTA per antibody seems to be the best ratio to maintaining a balance between radiochemical yield, immunoreactivity and pharmacokinetic behavior. Our next step would be to measure immunoreactivity to gain more insight about the possible mechanism.


Purpose :

Even if the TEM-1 positive uptake was specific, we also observed an important liver uptake that was not saturation-dependent. Our hypothesis for this phenomenon was the influence of the number of chelator (DOTA) on the biodistribution.

The aim of this study was to verify this hypothesis and find the best ratio of DOTA per antibody to develop an optimal radiolabeled compound for theranostic applications.

Materials and methods

1C1m was conjugated with six different concentrations of DOTA (evaluated by mass spectrometry).



The different conjugates were radiolabelled with 177Lu and injected in mice bearing TEM-1 positive tumors.


In each group, three animals were euthanized by CO2 inhalation and exsanguinated at 24h after injection of the radiolabeled product.

Blood was collected, organs and tumors were removed, weighed, and the activity was measured by gamma counter.


Results

Number of DOTA per 1C1m-Fc	Bmax (cpm)	Total Act (cpm)	Immunoreactivity (%)
1	1742	2046	85.1
3	3200	4540	70.5
6	2234	2553	87.5
85	3557	1511	78

Biodistribution at 24 hours of [177Lu]Lu-1C1m-Fc conjugated with 1 to 11 DOTA in Balb/c nu mice bearing TEM-1 positive tumour. Data are shown as mean \pm SD.



Ratio between the tumour and the liver mean uptake at 24 h regarding the number of DOTA per [177Lu]Lu-1C1m-Fc in Balb/c mice bearing TEM-1 positive tumour. Spearman test giving a rho = - 0.99, p < 0.0001



Lindmo assays results for [177Lu]Lu-1C1m-Fc conjugated with 1 to 11 DOTA. No correlation between the IR and the number of DOTA until 8.5. Dramatical loose of IR for 1C1m-Fc conjugated with 11 DOTA.



Contact : Judith.delage@chuv.ch

	1 DOTA	3 DOTA
Source organ	Mean Abs Dose (mGy/MBq)	Absorbed dose (mGy/MBq)
Tumor SK-N-AS	2.53E+03	1.82E+03
Liver	1.79E+03	2.23E+03
Kidneys	1.32E+03	7.05E+02
Lungs	9.83E+02	5.39E+02
Spleen	1.18E+03	1.20E+03
Uterus	1.83E+03	1.5 E+03

Mouse dosimetry comparison between [177Lu]Lu-1C1m-Fc conjugated with 1 or 3 DOTA.

Tumor/Liver ratio multiplied by 1.7 with the 1C1m-Fc conjugated with 1 DOTA vs 3 DOTA.